MRK Stock Analysis

Key Financial Metrics

📊Valuation

P/E Ratio
19.28
Forward P/E
16.52
P/S Ratio
1.33
P/B Ratio
5.51
EV/EBITDA
13.97
EV/Revenue
1.43
PEG Ratio
1.53

💰Profitability

Gross Margin
37.5%
Operating Margin
25.6%
Net Margin
19.1%
ROE
25.8%
ROA
8.9%
ROIC
16.5%

📈Growth

Revenue Growth (YoY)
5.9%
EPS Growth (YoY)
8.6%
FCF Growth
11.4%

🏦Financial Health

Debt/Equity
0.80
Current Ratio
1.46
Quick Ratio
1.17
Interest Coverage
12.85

💵Dividends

Dividend Yield
1.6%
Payout Ratio
30.8%
Dividend Growth
5.5%

📋Per Share

EPS
$27.11
Book Value/Share
$93.98
FCF/Share
$21.76
Revenue/Share
$97.61

Proprietary Model

Finlytics Score

Instant view of the current conviction score for MRK, with component-level transparency.

Refreshing score...Loading live inputs

Pro Feature

Peer Comparison

Compare valuation, growth, margins, and Finlytics Score against the closest sector names.

Previewing 2 peers

🔒 See full peer comparison with Pro — $29/month

Upgrade to Pro

Company overview

About Merck & Company, Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Finlytics combines this business profile with an interactive DCF valuation, bear/base/bull intrinsic value scenarios, financial statements, peer comparison, and the Finlytics Score so investors can evaluate MRK stock from multiple angles.

Finlytics Score
72/100
Trailing P/E
118.7
Revenue Growth
+5.1%
Market Cap
$368.9B

Price History

1Y Performance: +15.17%

Financial Statements

Reported fundamentals across filing periods

Revenue, margins, and earnings power across reported periods.

Positive changeNegative change

Annual filings

Loading statement history